Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)
Information source: University of California, San Diego
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: CLL
Intervention: Ofatumumab/HDMP (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Januario Castro, M.D. Official(s) and/or principal investigator(s): Januario Castro, MD, Principal Investigator, Affiliation: University of California, San Diego Thomas J Kipps, MD, PhD, Principal Investigator, Affiliation: Director of the CLL Research Consortium and University of California San Diego
Summary
Patients who have relapsed/refractory CLL and require therapy as per iwCLL guidelines will
be eligible. Subjects will receive a treatment with ofatumumab and HDMP for three
consecutive 4 week cycles. The primary endpoint is to determine the complete response (CR)
to therapy and the secondary endpoints will assess the safety and tolerability of the
regimen, the impact of the treatment on progression free, treatment free, overall survival,
and pharmacokinetics of ofatumumab. Patients will receive allopurinol for tumor-lysis
prophylaxis and antimicrobial prophylaxis.
Clinical Details
Official title: A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: IwCLL-WG defined complete remissions
Secondary outcome: Adverse events associated with Ofatumumab-HDMP combination regimen.Progression free, treatment free and overall survival. pharmacokinetics of ofatumumab. Minimal residual disease (MRD) following therapy
Detailed description:
Patients who have relapsed/refractory CLL and require therapy as per iwCLL guidelines will
be eligible. Subjects will receive a treatment with ofatumumab and HDMP for three
consecutive 4 week cycles. The primary endpoint is to determine the complete response (CR)
to therapy and the secondary endpoints will assess the safety and tolerability of the
regimen, the impact of the treatment on progression free, treatment free, overall survival,
and pharmacokinetics of ofatumumab. Cycles 1-3 will be administered without scheduled
interruption every 28 days for a total of 12 weeks of therapy. Patients will receive
allopurinol for tumor-lysis prophylaxis and antimicrobial prophylaxis. Blood glucose
levels will be monitored immediately after HDMP infusion by finger stick glucometry. Two
months following completion of treatment a response assessment will occur per iwCLL
guidelines. The treatment will be administered as outpatient, and each cycle will be four
weeks in duration.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Previously treated patients with a diagnosis of CLL
2. Previous treatment with any monoclonal antibody or chemotherapy regardless of
response as defined by the iwCLL Working Group Guidelines as evidenced by:
- progressive marrow failure as manifested by the development of, or worsening of,
anemia and/or thrombocytopenia
- massive (i. e. at least 6cm below the left costal margin) or progressive or
symptomatic splenomegaly
- massive nodes (i. e. at least 10cm in longest diameter) or progressive or
symptomatic lymphadenopathy.
- progressive lymphocytosis with an increase of more than 50% over a 2-month
period or lymphocyte doubling time (LDT) of less than 6 months.
- autoimmune anemia and/or thrombocytopenia that is poorly responsive to
corticosteroids or other standard therapy (See Section 10. 2)
3. Constitutional symptoms, defined as any one or more of the following disease-related
symptoms or signs: unintentional weight loss of 10% or more within the previous 6
months significant fatigue (i. e. ECOG PS 2 or worse, inability to work or perform
usual activities), fevers higher than 100. 5ºF or 38. 0ºC for 2 or more weeks without
other evidence of infection, night sweats for more than 1 month without evidence of
infection
4. Subjects must be 18 years of age or older, male or female.
5. ECOG performance status of 0-2.
6. Subjects must be able to give informed consent.
7. Females of child bearing potential(FCBP)† must have a negative serum or urine
pregnancy test within 10 - 14 days prior to and again within 24 hours of starting
treatment and agree to use a medically accepted contraceptive method for the duration
of this study.
Exclusion Criteria:
1. Hepatitis BsAg positive, Hepatitis BcAb positive, and Hepatitis C positive patients.
2. Known HIV positive patients.
3. Diabetics.
4. Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) or autoimmune
thrombocytopenia (ITP).
5. Screening laboratory values within these ranges: platelets <50 x 109/L, neutrophils
<1. 0 x 109/L, creatinine >2. 0 times upper normal limit,total bilirubin >1. 5 times
upper normal limit (unless a known history of Gilbert's disease), ALT >2. 5 times
upper normal limit (unless due to disease involvement of liver), alkaline phosphatase
>2. 5 times upper normal limit (unless due to disease involvement of the liver or bone
marrow)
6. Inability to provide informed consent.
7. Concurrent malignancy (excluding basal and squamous cell skin cancers).
8. Active fungal, bacterial, and/or viral infection.
9. History of peptic ulcer disease resulting in GI bleeding within the last 6 months.
10. Untreated metabolic disorders such as hypothyroidism and Cushing's disease.
11. History of steroid-induced psychosis.
12. Estimated life expectancy of less than 3 months by the investigator's best clinical
judgment.
13. Serious medical condition that would render the subject medically unstable.
14. Women who are pregnant or breast-feeding.
15. History of Pancreatitis.
16. History of Diverticulitis.
17. Patients with known hypersensitivity to ofatumumab or known history of anaphylaxis to
Rituximab or alemtuzumab.
18. Concurrent use of other anti-cancer agents or treatments.
19. Subjects who have current active hepatic or biliary disease (with exception of
patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable
chronic liver disease per investigator assessment).
Locations and Contacts
UC San Diego Moores Cancer Center, La Jolla, California 92093, United States
University of California San Diego, Moores Cancer Center, La Jolla, California 92093, United States
Additional Information
Moore's UCSD Cancer Center Website for the Chronic Lymphocytic Leukemia Research Consortium
Related publications: Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct;23(10):1779-89. doi: 10.1038/leu.2009.133. Epub 2009 Aug 20. Erratum in: Leukemia. 2009 Dec;23(12):2326. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008 Nov;22(11):2048-53. doi: 10.1038/leu.2008.214. Epub 2008 Aug 28.
Starting date: August 2010
Last updated: September 6, 2013
|